Angelika Hanschmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angelika Hanschmann has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Christina Marciniak
Rehabilitation Institute of Chicago Chicago IL United States
3 shared publications Elie Elovic
Renown Rehabilitation Hospital Reno NV United States
3 shared publications- Michael C. Munin
Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
3 shared publications - Petr Kaňovský
Department of Neurology and Clinical Neuroscience Center, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
2 shared publications Reinhard Hiersemenzel
Merz Pharmaceuticals GmbH Frankfurt am Main Germany
2 shared publications- Allison Brashear
Jacobs School of Medicine and Biomedical Sciences University at Buffalo, Buffalo, NY, USA
1 shared publication
Latest Publications
- Open Access
- 1 August 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 563-572
Facial skin revitalization with CPM®-HA20G: an effective and safe early intervention treatment
Background: Hyaluronic acid (HA) fillers are popular for the treatment of signs of facial skin aging. Objective: The objective of this study was to confirm the performance and safety of a new cohesive polydensified matrix HA filler ([CPM®-HA20G, Belotero Revive,® lidocaine-free], Merz Pharmaceuticals GmbH, Frankfurt, Germany) for the treatment of early signs of facial skin aging by use of biophysical measurements as well as subject and investigator satisfaction. Methods: Twenty-five healthy female subjects with signs of facial skin aging were enrolled in this open-label, rater-blinded, observational post-market clinical follow-up study, and received 20 micropuncture treatments of 50 μL CPM®-HA20G each into the lower cheek area at three injection visits 4 weeks apart. Objective biophysical assessments were conducted to demonstrate effects on viscoelastic properties of the skin, surface roughness, tone and radiance, and hydration, at baseline and at all follow-up visits up to 36 weeks. Results: CPM®-HA20G significantly increased gross elasticity of the skin (at weeks 9 and 12), skin firmness (up to week 24), skin tone and radiance and skin hydration (all up to 36 weeks). Significant reduction of skin fatigue (up to 9 weeks), skin roughness (up to 28 weeks), and redness (up to 36 weeks) was also observed. Subjects and blinded investigator were highly satisfied with the treatment outcomes. The treating investigator reported a high level of satisfaction with the ease of injection and the clinical performance of the device. Moreover, data demonstrated a good safety profile of the device. Conclusion: CPM®-HA20G is considered to be an effective and safe HA injectable for skin revitalization in patients suffering from signs of skin aging and loss of skin elasticity. It seems to be a perfect early intervention approach in patients that do not need volumizing treatment and a combination approach in older patients with more pronounced aging.
- 1 August 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 563-572
Open AccessFacial skin revitalization with CPM®-HA20G: an effective and safe early intervention treatment
Background: Hyaluronic acid (HA) fillers are popular for the treatment of signs of facial skin aging. Objective: The objective of this study was to confirm the performance and safety of a new cohesive polydensified matrix HA filler ([CPM®-HA20G, Belotero Revive,® lidocaine-free], Merz Pharmaceuticals GmbH, Frankfurt, Germany) for the treatment of early signs of facial skin aging by use of biophysical measurements as well as subject and investigator satisfaction. Methods: Twenty-five healthy female subjects with signs of facial skin aging were enrolled in this open-label, rater-blinded, observational post-market clinical follow-up study, and received 20 micropuncture treatments of 50 μL CPM®-HA20G each into the lower cheek area at three injection visits 4 weeks apart. Objective biophysical assessments were conducted to demonstrate effects on viscoelastic properties of the skin, surface roughness, tone and radiance, and hydration, at baseline and at all follow-up visits up to 36 weeks. Results: CPM®-HA20G significantly increased gross elasticity of the skin (at weeks 9 and 12), skin firmness (up to week 24), skin tone and radiance and skin hydration (all up to 36 weeks). Significant reduction of skin fatigue (up to 9 weeks), skin roughness (up to 28 weeks), and redness (up to 36 weeks) was also observed. Subjects and blinded investigator were highly satisfied with the treatment outcomes. The treating investigator reported a high level of satisfaction with the ease of injection and the clinical performance of the device. Moreover, data demonstrated a good safety profile of the device. Conclusion: CPM®-HA20G is considered to be an effective and safe HA injectable for skin revitalization in patients suffering from signs of skin aging and loss of skin elasticity. It seems to be a perfect early intervention approach in patients that do not need volumizing treatment and a combination approach in older patients with more pronounced aging.
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Duration of Treatment Effect of IncobotulinumtoxinA in Upper Limb Spasticity (P4.036)
- 18 April 2017
- Published by Wolters Kluwer Health in Neurology
- Vol. 88 (16_supplem)
Duration of Treatment Effect of IncobotulinumtoxinA in Upper Limb Spasticity (P4.036)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Sustained Efficacy with IncobotulinumtoxinA in Upper-Limb Post-Stroke Spasticity Over 48 Weeks (a Phase 3, Placebo-Controlled Study with an Open-Label Extension) (P3.303)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Sustained Efficacy with IncobotulinumtoxinA in Upper-Limb Post-Stroke Spasticity Over 48 Weeks (a Phase 3, Placebo-Controlled Study with an Open-Label Extension) (P3.303)
- Open Access
- 1 November 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 346 (1-2) , 116-120
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated
- 1 November 2014
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 346 (1-2) , 116-120
Open AccessIncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated